Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Buspirone/Zolmitriptan - Contera Pharma

Next Previous
Search
Drug Profile

Buspirone/Zolmitriptan - Contera Pharma

Alternative Names: AV-2860; JM-010

Latest Information Update: 03 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Contera Pharma
  • Developer Bukwang Pharmaceutical; Contera Pharma
  • Class Antidepressants; Antimigraines; Antiparkinsonians; Anxiolytics; Oxazolidinones; Pyrimidines; Small molecules; Spiro compounds; Tryptamines
  • Mechanism of Action 5-HT1A serotonin receptor agonists; Dopamine modulators; Neurotransmitter agents; Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Drug-induced dyskinesia

Most Recent Events

  • 10 Oct 2024 Contera Pharma terminates the phase II trial in Parkinson's disease patients with dyskinesia in Italy and Spain based on business decision, not due to safety concerns or regulatory requirements (NCT05516875)
  • 21 May 2024 Efficacy and adverse events data from a phase IIb ASTORIA trial in Drug-induced dyskinesia released by Contera Pharma
  • 21 Mar 2024 Contera Pharma completes the Phase-II ASTORIA clinical trials in Drug-induced dyskinesia in France, Germany, Italy, South Korea, Spain, Slovakia (PO) (NCT03956979)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top